Strong Revenue and EPS Growth
In Q3 2025, Siemens Healthineers achieved a revenue growth of 7.6% and a significant EPS increase of 23% to EUR 0.64 per share, despite a EUR 100 million tariff impact.
Impressive Imaging and Varian Segment Performance
Imaging segment saw revenue growth of almost 12% with a strong margin of 21%, while Varian reported 9% comparable revenue growth with a margin recovery to 18.8%.
Expansion of Value Partnerships
Value Partnerships revenue has grown threefold since the IPO, contributing to over 5% of total revenue, with significant deals signed in the U.S., Germany, and France exceeding EUR 100 million.
Diagnostics Margin Improvement
Despite slightly negative growth, Diagnostics achieved a margin of 9.2%, with the Atellica franchise growing double digits, accounting for 60% of core lab revenues.
Free Cash Flow and Deleveraging
Free cash flow increased by 50% year-over-year, reducing the leverage factor below 3x for the first time since the Varian acquisition.